Cannabinoids for gastrointestinal diseases: potential therapeutic applications

Bibliography

• WILLIAMSON EM, EVANS FJ: Cannabinoids in clinical practice. Drugs (2000) 60:1303–1314.
   PubMed Web of Science ®Google Scholar
• GRINSPOON L, BAKALAR JB: Marihuana - the Forbidden Medicine Yale University Press, New Haven, CT, USA (1997).
   Google Scholar
• NOCERINO E, AMATO M, IZZO AA: Cannabis and cannabinoid receptors. Fitoterapia (2000) 71:S6–S12.
   PubMed Web of Science ®Google Scholar
• PORTER AC, FELDER CC: The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Thar: (2001) 90:45–60.
   PubMed Web of Science ®Google Scholar
• PERTWEE RG, ROSS RA: Cannabinoidreceptors and their ligands. Prostaglandins Leucotr. Essent. Fatty Acids (2002) 66:101–121.
   PubMed Web of Science ®Google Scholar
• HOWLETT AC, BARTH F, BONNER TJ et al: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 54:161–202.
   Google Scholar
• •This review summarises the main features of the structure, pharmacology and function of cannabinoid receptors that provide the basis for the classification of these receptors.
   Google Scholar
• MECHOULAM R: Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leucotr. Essent Fatg Acids (2002) 66:93–99.
   PubMed Web of Science ®Google Scholar
• GIUFFRIDA A, BELTRAMO B, PIOMELLI D: Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. Pharmacol Exp. Thar. (2001) 298:7–14.
   PubMed Web of Science ®Google Scholar
• DEVANE WA, DYSARZ FAI, JOHNSON MR, MELVIN LS, HOWLETT AC: Determination and characterization of a cannabinoid receptor in rat brain. Ma Pharmacol (1988) 34:605–613.
   PubMed Web of Science ®Google Scholar
• MATSUDA LA, LOLAIT SJ, BROWNSTEIN BJ, YOUG AC, BONNER TL: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346:561–564.
   PubMed Web of Science ®Google Scholar
• MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61–65.
   PubMed Web of Science ®Google Scholar
• DEVANE WA, HANUS L, BREUER A et al.: Isolation and structure of a brain constituent that binds to the cannabinoidreceptor. Science (1992) 258:1946–1949.
   PubMed Web of Science ®Google Scholar
• MECHOULAM R, BEN-SHABAT S, HANUS L et al: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to a cannabinoid receptor. Biochem. Pharmacol (1995) 50:83–90.
   PubMed Web of Science ®Google Scholar
• SUGIURA T, KONDO S, SUKAGAWA A et al.: 2-arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. (1995) 215:89–97.
   PubMed Web of Science ®Google Scholar
• HANUS L, ABU-LAFI S, FRIDE E et al:2-Arachidonyl glyceryl ether, an endogenous agonists of the cannabinoid CBI. receptor. Proc. Natl. Acad. Sci. USA (2001) 98:3662–3665.
   PubMed Web of Science ®Google Scholar
• ZYGMUNT PM, PETERSSON J, ANDERSSON DA et al.: Vanilloid receptors on sensory nerves mediate the vasodilatator action of anandamide. Nature (1999) 400:452–457.
   PubMed Web of Science ®Google Scholar
• PORTER AC, SAUER JM, KNIERMAN MD et al.: Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CBI. receptor. Pharmacol Exp. Thar. (2002) 301:1020–1024.
   PubMed Web of Science ®Google Scholar
• WILSON RI, NICOLL RA: Endocannainoid signaling in the brain. Science (2002) 296:678–682.
   PubMed Web of Science ®Google Scholar
• •This review discusses the notion that endogenous cannabinoids can function as retrograde synaptic messengers and affect memory, cognition and pain perception by means of this cellular mechanism.
   Google Scholar
• ELPHICK MR, EGERTOVA M: The neurobiology and evolution of cannabinoid signalling. Philos. Trans. R. Soc. Lond. B Biol. Sci (2001) 356:381–408.
   PubMed Web of Science ®Google Scholar
• FOWLER CJ, JACOBSSON SOP: Cellulartransport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide - targets for drug development? Prostaglandins Leucotr. Essent. Fatty Acids (2002) 66:193–200.
   PubMed Web of Science ®Google Scholar
• SUGIURA T, KOBAYASHI Y, OKA S, WAKU K: Biosynthesis and degradation of anandamide and 2-arachidonylglycerol and their possible physiological significance. Prostaglandins Leucotr. Essent. Fatty Acids (2002) 66:173–192
   PubMed Web of Science ®Google Scholar
• DEUTSCH DG, UEDA N, YAMAMOTO S: The fatty acid amide hydrolase (FAAH). Prostaglandins Leucotr. Essent. Fatty Acids (2002) 66:201–210.
   PubMed Web of Science ®Google Scholar
• PERTWEE RG: Cannabinoid and the gastrointestinal tract. Gut (2001) 48:859–897.
   PubMed Web of Science ®Google Scholar
• IZZO AA, MASCOLO N, CAPASSO F: The gastrointestinal pharmacology of cannabinoids. Curt: Opin. Pharmacol (2001) 1:597–603.
   PubMedGoogle Scholar
• PINTO L, CAPASSO R, DI CARLO G, IZZO AA: Endocannabinoids and the gut. Prostaglandins Leucotr. Essent. Fatty Adds (2002) 66:333–341.
   PubMed Web of Science ®Google Scholar
• ADAMI M, FRATI P, BERTINI S et al: Gastric antisecretory role and immunohistochemical localisation of cannabinoid receptors in the rat stomach. Br.Pharmacol (2002) 135:1598–606.
   PubMed Web of Science ®Google Scholar
• •Pharmacological and irnmuno-histochemical evidence for an acid gastric antisecretory role of CB]. receptors.
   Google Scholar
• COUTTS AA, IRVING AJ, MACKIE K, PERTWEE RG, ANAVI-GOFFER S: Localisation of cannabinoid CBI receptor immunoreactivity in the guinea pig and rat myenteric plexus. Comp. Neurol (2002) 448:410–422.
   PubMed Web of Science ®Google Scholar
• PINTO L, IZZO AA, CASCIO MG et al: Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology (2002) 123:227–234.
   PubMed Web of Science ®Google Scholar
• •The paper reports the biochemical and pharmacological basis for the possible use of the uptake inhibitor VDM11 in the control of hyperactivated intestinal motility.
   Google Scholar
• MASCOLO N, IZZO AA, LIGRESTI A et al.: The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB (2002) 16:1973–1975.
   PubMed Web of Science ®Google Scholar
• •The paper reports the biochemical and pharmacological basis for the possible use of non-psychotropic CBI antagonists in paralytic ileus.
   Google Scholar
• KULKARNI-NARLA A, BROWN DR Localization of CBi-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res. (2000) 302:73–80.
   PubMed Web of Science ®Google Scholar
• KULKARNI-NARLA A, BROWN DR: Opioid, cannabinoid and vanilloid receptor localization on porcine cultured myenteric neurons. Neurosc. Lett. (2001) 308:153–156.
   PubMed Web of Science ®Google Scholar
• IZZO AA, FEZZA F, CAPASSO R et al.:Cannabinoid CBi-receptor mediated regulation of gastrointestinal motility in mice in a chronic model of intestinal inflammation. Br. I Pharmacol (2001) 134:563–570.
   PubMed Web of Science ®Google Scholar
• MANG CF, ERBELDING D, KILBINGER H: Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-C131 cannabinoid receptors. Br. Phannacol (2001) 134:161–167.
   Web of Science ®Google Scholar
• STORR M, GAFFAL E, SAUR D, SCHUSDZIARRA V, ALLESHER HD: Effect of cannabinoids on neural transmission in rat gastric fundus. Can. J. Physiol Phannacol (2002) 80:67–76.
   PubMed Web of Science ®Google Scholar
• KATAYAMA K, UEDA N, KURAHASHI Y, SUZUKI H, YAMAMOTO S, KATO I: Distribution of anandamide amidohydrolase in rat tissues with a special reference to small intestine. Biochitn. Biophys. Acta (1997) 1347:212–218.
   PubMed Web of Science ®Google Scholar
• PERTWEE RG, FERNANDO SR, GRIFFIN G, ABADJI V, MAKRIYANNIS A: Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur. Phannacol (1995) 272:73–78.
   PubMed Web of Science ®Google Scholar
• REGGIO PH: Endoeannabinoid structure-activity relationships for interaction at the cannabinoid receptors. Prostaglandins Leucotr. Essent. Fato Acids (2002) 66:161–172.
   PubMedGoogle Scholar
• PERTWEE RG: Cannabinoid receptor ligands: clinical and neuropharmacological considerations relevant to future drug discovery and development. Expert Opin. Invest. Drugs (2000) 9:1553–1571.
   PubMed Web of Science ®Google Scholar
• PIOMELLI D, GIUFFRIDA A, CALIGNANO A, RODRIGUEZ DE FONSECA F: The endocannabinoid system as a target for therapeutic drugs. Trends Phannacol Sci. (2000) 21:218–224.
   PubMed Web of Science ®Google Scholar
• DE PETROCELLIS L, BISOGNO T, DAVIS JB, PERTWEE RG, DI MARZO V: Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. (2000) 483:52–56.
   PubMed Web of Science ®Google Scholar
• TRAMER MR, CARROL D, CAMPBELL FA et al: Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMI (2001) 323:16–21.
   PubMed Web of Science ®Google Scholar
• •A systematic review on the antiemetic efficacy and adverse effect of cannabis used for nausea and vomiting induced by chemotherapy.
   Google Scholar
• GRALLA RA: Cannabinoids and the control of chemotherapy-induced nausea and vomiting. In: Marijuana and Medicine. GC Nahas, KM Sutin, DJ Harvey, S Agurell (Eds), Humana Press, Totowa, NJ, USA (1999).
   Google Scholar
• DARMANI NA: The cannabinoid C131 receptor antagonist 5R141716A reverses the antiemetic and motor depressant actions of WIN55,212-2. Eur.j Phannacol (2001) 430:49–58.
   PubMed Web of Science ®Google Scholar
• DARMANI NA: Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Phannacol Biochetn. Behav. (2001) 69:239–249.
   PubMed Web of Science ®Google Scholar
• DARMANI NA: Delta-9-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/ inverse agonist 5R141716A. Neuropsycophannacology (2001) 150:200–207.
   Google Scholar
• VAN SICKLE MD, OLAND LD, HOW et al.: Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology (2001) 121:767–774.
   PubMed Web of Science ®Google Scholar
• •The paper reports that cannabinoids are effective antiemetics and part of an endogenous system that can modulate emesis.
   Google Scholar
• FARHADI A, BRUNINGA K, FIELDS J, KESHAVARZIAN A: Irritable bowel syndrome: an update on therapeutic modalities. Expert Opin. Investig. Drugs (2001) 10:1211–1222.
   PubMed Web of Science ®Google Scholar
• PERTWEE RG, FERNANDO SR, NASH JE, COUTTS AA: Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br. I Phannacol (1996) 118:2199–2205.
   Web of Science ®Google Scholar
• IZZO AA, MASCOLO N, BORRELLI F, CAPASSO F: Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CBI. receptors. Br. Phannacol (1998) 124:1363–1368.
   Web of Science ®Google Scholar
• HEINEMANN A, SHAHBAZIAN A, HOLZER P: Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neurla pathways. Neurophannacology (1999) 38:1289–1297.
   PubMed Web of Science ®Google Scholar
• IZZO AA, MASCOLO N, TONINI M, CAPASSO F: Modulation of peristalsis by cannabinoid CB1 ligands in the isolated guinea-pig ileum. Br. Phannacol (2000) 129:984–990.
   Web of Science ®Google Scholar
• MANCINELLI R, FABRIZI A, DEL MONACO S et al.: Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse. Life Sci. ( 2001) 69:101–111.
   Google Scholar
• CROCI T, MANARA L, AUREGGI G et al.: Li vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br. J. Phannacol (1998) 125:1393–1395.
   Web of Science ®Google Scholar
• MANARA L, CROCI T, GUAGNINI F et al.: Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. Digest. Liver Dis. (2002) 34:262–269.
   Web of Science ®Google Scholar
• •The paper reports functional evidence for the presence of CB1 receptors in the human colon.
   Google Scholar
• IZZO AA, MASCOLO N, CAPASSO R, GERMANO MP, DE PASQUALE R, CAPASSO F: Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn-Scluniedebergs Arch. Phannacol (1999) 360:221–223.
   PubMed Web of Science ®Google Scholar
• KROWICKI ZK, MOERSCBAECHER JM, WINSAUER PJ, DIVAGALLI SV, HORNBY PJ: A9-Tetrahydrocannainol inhibits gastric motility in the rat through cannabinoid C131 receptors. Eur. Phannacol (1999) 37:187–196.
   Google Scholar
• LANDI M, CROCI T, RINALDI-CARIVIONA M, MAFFRAND J-P, LE FUR G, MANARA L: Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid C131 receptors. Eur. Phannacol (2002) 450:77–83.
   PubMed Web of Science ®Google Scholar
• CALIGNANO A, LA RANA G, MAKRIAYANNIS A, LIN SY, BELTRAMO M, PIOMELLI D: Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur.j Phannacol (1997) 340:R7–R8.
   PubMed Web of Science ®Google Scholar
• COLOMBO G, AGABIO R, LOBINA C, REALI R, GESSA GL: Cannabinoid modulation of intestinal propulsion in mice. Eur Phannacol (1998) 344:67–69.
   PubMed Web of Science ®Google Scholar
• IZZO AA, MASCOLO N, BORRELLI F, CAPASSO F: Defeacation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 ligands in the isolated guinea pig ileum. Naunyn-Saniedebergs Arch. Phannacol (1999) 359:65–70.
   PubMed Web of Science ®Google Scholar
• CARAI MAM, AGABIO R, LOBINA C et al.: Relationship between cannabinoid CB1 and dopamine D2 receptors in intestinal motility in mice. Pharm. Pharmacol Commun. (2000) 6:287–291.
   Google Scholar
• IZZO AA, CAPASSO R, PINTO L, DI CARLO G, MASCOLO N, CAPASSO F: Effect of vanilloid drugs on gastrointestinal transit in mice. Br. .1. Pharmacol (2001) 132:1411–1416.
   PubMed Web of Science ®Google Scholar
• IZZO AA, PINTO L, BORRELLI F, CAPASSO R, MASCOLO N, CAPASSO F. Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. ELI Pharmacol (2000) 129:1627–1632.
   Web of Science ®Google Scholar
• IZZO AA, MASCOLO N, PINTO L, CAPASSO R, CAPASSO F: The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Ear: Pharmacol (1999) 384:37–42.
   PubMed Web of Science ®Google Scholar
• McCALLUM RW, SOYKAN I, SRIDHAR KR, RICCI DA, LANGE RC, PLANKEY MW: Delta-9-tetrahydrocannabinol delays the gastric emptyng of solid food in humans: a double-blind, randomised study. Aliment. Pharmacol Ther. (1999) 13:77–80.
   PubMed Web of Science ®Google Scholar
• BITTON A, PEPPERCORN MA: Medicalmanagement of Crohn's disease. In: Gastrointestinal Pharmacology and Therapeutics. G Friedman, E Jacobson, R McCallum (Eds), Lippincott-Raven, Philadelphia, PA, USA (1997).
   Google Scholar
• LIVINGSTON EH, PASSARO EP: Postoperative ileus. Dig. Dis. Sci. 35:121–132.
   Google Scholar
• KAHRILAS PJ: Gastroesophageal reflux disease. In: Gastrointestnal Pharmacology and Therapeutics. G Friedman, E Jacobson, R McCallum (Eds), Lippincott-Raven, Philadelphia, PA, USA (1997).
   Google Scholar
• FASS R, OFMAN JJ: Gastroesophageal reflux disease-should we adopt a new conceptual framework? Am. J. Gastroenterol (2002) 97:1901–1909.
   Web of Science ®Google Scholar
• LEHMANN A, ASHLEY BLACKSHAW L, BRANDEN L et al.: Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology (2002) 123:1129–1134.
   PubMed Web of Science ®Google Scholar
• •The paper reports that cannabinoid CBI agonists may be effective in gastroesophageal reflux by inhibiting transient LES relaxation.
   Google Scholar
• CHANG EB: The pathophysiology of diarrhea and constipation. In: Gastrointestinal Pharmacology and Therapeutics. G Friedman, E Jacobson, R McCallum (Eds), Lippincott-Raven, Philadelphia, PA, USA (1997).
   Google Scholar
• TYLER K, HILLARD CJ, GREENWOOD-VAN MEERVELD B: Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. Eur. Pharmacol (2000) 409:207–211.
   PubMed Web of Science ®Google Scholar
• SOFIA RD, DIAMANTIS W, HARRISON JE et al.: Evaluation of antiulcer activity of 49-tetrahydrocannabinol in Shay rat test. Pharmacology (197 8) 17:173–177.
   Google Scholar
• CORUZZI G, ADAMI M, COPPELLI G, FRATI P, SOLDANI G: Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetised rat. Naunyn-Schmiedebergs Arch. Pharmacol (1999) 360:715–718.
   PubMed Web of Science ®Google Scholar
• GERMANO MP, D'ANGELO V, MONDELLO MR et al.: Cannabinoid CBi-mediated inhibition of stress-induced gastric ulcers in rats. Naunyn-Schmiedebergs Arch. Pharmacol (2001) 363:241–244.
   Google Scholar
• •Pharmacological evidence for a protective role of CB1 receptors in an experimental model of gastric ulcer.
   Google Scholar
• NALIN DR, RHEAD J, RENNELS M et al.: Cannabis, hypochlorhydria and cholera. Lancet (1978) 2:859–862.
   PubMed Web of Science ®Google Scholar
• CAPASSO R, IZZO AA, FEZZA F et al: Inhibitory effect of palmitoylethanolamide on intestinal motility in mice. Br. J. Pharmacol (2001) 134:945–950.
   PubMed Web of Science ®Google Scholar
• SHOOK JE, BURKS TF: Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J. Pharmacol Exp. Ther. (1989) 249:444–449.
   PubMed Web of Science ®Google Scholar